Company Filing History:
Years Active: 2023-2025
Title: **Innovative Contributions of Daniel Ulej in Pharmaceutical Chemistry**
Introduction
Daniel Ulej is an accomplished inventor based in Budapest, Hungary. He is recognized for his significant contributions to pharmaceutical chemistry, particularly in the development of new methods for drug production. His expertise has led to the creation of an innovative method for producing lumateperone, a compound with therapeutic potential.
Latest Patents
Daniel holds one patent, titled "Method for the production of lumateperone and its salts." This patent details a process wherein lumateperone or its acid addition salts are produced through careful stereochemical resolution and alkylation. Specifically, the method involves separating the enantiomer compound with stereochemistry 6bR,10aS from the cis racemate, followed by alkylation with 4-halo-4'-fluoro butyrophenone. Furthermore, the patent covers the amorphous form of the morphologically uniform p-toluenesulfonic acid salt of lumateperone, along with its naphthalene-2-sulfonic acid salt.
Career Highlights
Daniel is associated with Egis Gyogyszergyar Zrt., a prominent company in the pharmaceutical industry. His work at Egis has positioned him as a key player in advancing drug formulation technologies. With his innovative approach to production methods, Daniel contributes significantly to the company's research and development endeavors.
Collaborations
Throughout his career, Daniel has collaborated with notable colleagues such as Gábor Berecz and Bálint Nyulasi. These collaborations emphasize a strong team dynamic centered around innovation and discovery in pharmaceutical chemistry.
Conclusion
Daniel Ulej exemplifies the role of inventors in the pharmaceutical industry, showcasing the impact of innovative methods on drug production. His patent for lumateperone production highlights his commitment to advancing medical science and improving therapeutic options for patients. As he continues to work at Egis Gyogyszergyar Zrt., Daniel remains a valuable contributor to research and innovation in pharmaceuticals.